Carfilzomib for relapsed or refractory multiple myeloma

被引：0
|
作者：
Tanimoto, Tetsuya [1 ]
Tsuda, Kenji [2 ]
Oshima, Kumi [1 ]
Mori, Jinichi [1 ]
Shimmura, Hiroaki [1 ]
机构：
[1] Tokiwa Fdn, Jyoban Hosp, Fukushima 9728322, Japan
[2] Teikyo Univ, Chiba Med Ctr, Chiba, Japan
来源：
LANCET ONCOLOGY | 2018年 / 19卷 / 01期
关键词：
BONE-DISEASE; BISPHOSPHONATE;
D O I：
10.1016/S1470-2045(17)30859-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E1 / E1
页数：1
相关论文
共 50 条
  • [21] Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
    Dubey, A. P.
    Khatri, Sameer
    Maggo, Sachin
    Singh, Nilabh K.
    Sharma, Durgesh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 846 - 849
  • [22] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
    Shah, Jatin J.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Cohen, Adam D.
    Bensinger, William I.
    Gasparetto, Cristina
    Kaufman, Jonathan L.
    Lentzsch, Suzanne
    Vogl, Dan T.
    Gomes, Christina L.
    Pascucci, Natalia
    Smith, David D.
    Orlowski, Robert Z.
    Durie, Brian G. M.
    BLOOD, 2015, 126 (20) : 2284 - 2290
  • [23] Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
    Chari, Ajai
    Larson, Sarah
    Holkova, Beata
    Cornell, Robert F.
    Gasparetto, Cristina
    Karanes, Chatchada
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Valent, Jason
    Lunning, Matthew
    Usmani, Saad Z.
    Anderson, Larry D., Jr.
    Chang, Lipo
    Lee, Yihua
    Pak, Yvonne
    Salman, Zeena
    Graef, Thorsten
    Bilotti, Elizabeth
    Chhabra, Saurabh
    LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2588 - 2594
  • [24] Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
    Lendvai, Nikoletta
    Landau, Heather
    Lesokhin, Alexander
    Tsakos, Ioanna
    Koehne, Guenther
    Chung, David
    Devlin, Sean
    Hassoun, Hani
    Giralt, Sergio A.
    BLOOD, 2012, 120 (21)
  • [25] Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma
    Xu, Wenjun
    Sun, Xuedong
    Wang, Baohong
    Guo, Hui
    ANNALS OF HEMATOLOGY, 2018, 97 (02) : 299 - 307
  • [26] The mutational landscape underlying carfilzomib and pomalidomide resistance in relapsed/refractory multiple myeloma
    Xu, Jing
    Giesen, Nicola
    Paramasivam, Nagarajan
    Goldschmidt, Hartmut
    Brors, Benedikt
    Raab, Marc S.
    Weinhold, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E83 - E84
  • [27] Peripheral Neuropathy Experience in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Carfilzomib
    Martin, Thomas G.
    ONCOLOGY-NEW YORK, 2013, 27 : 4 - 10
  • [28] Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
    Uysal, Ayse
    Akad Soyer, Nur
    Ozkan, Melda
    Sahin, Fahri
    Vural, Filiz
    Tobu, Mahmut
    Tombuloglu, Murat
    Saydam, Guray
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2018, 48 (01) : 80 - 83
  • [29] Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Yi, Lidan
    Liu, Qiao
    Tan, Chongqing
    Wan, Xiaomin
    Luo, Xia
    Li, Yinbo
    Li, Haiying
    Zeng, Xiaohui
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2024, 17 : 2829 - 2837
  • [30] Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma
    Wenjun Xu
    Xuedong Sun
    Baohong Wang
    Hui Guo
    Annals of Hematology, 2018, 97 : 299 - 307
12345